(MedPage Today) — A short course of androgen deprivation therapy (ADT) added to stereotactic body radiotherapy (SBRT) halved the risk of disease progression or death in patients with metachronous oligometastatic hormone-sensitive prostate cancer…

Read the full article on medpagetoday.com